BackgroundThe recent crisis of refugees seeking asylum in European countries challenges public health on many levels. Most refugees currently arrive from Syria, Afghanistan, or Eritrea. Data about multidrug resistant bacteria (MDR) prevalence are not present for these countries. However, when entering the European heath care systems, data about colonisation rates regarding highly resistant bacterial pathogens are important.MethodsWe performed a cross-sectional screening in four Swiss refugee centres to determine the colonization rates for MRSA and ESBL- and carbapenemase-producing Enterobacteriaceae. We used pharyngeal, nasal, and inguinal swabs for MRSA and rectal swabs and urine for ESBL and carbapenemase screening using standard microbiological procedures. Whole genome sequencing (WGS) was used to determine the relatedness of MRSA isolates with high resolution due to a suspected outbreak.Results41/261(15.7%) refugees were colonized with MRSA. No differences regarding the country of origin were observed. However, in a single centre significantly more were colonized, which was confirmed to be a recent local outbreak. 57/241 (23.7%) refugees were colonized with ESBL with significantly higher colonisation in persons originating from the Middle East (35.1%, p<0.001). No carbapenemase producers were detected.ConclusionThe colonisation rate of the refugees was about 10 times higher for MRSA and 2–5 times higher for ESBL compared to the Swiss population. Contact precaution is warranted for these persons if they enter medical care. In cases of infections, MRSA and ESBL-producing Enterobacteriaceae should be considered regarding antibiotic treatment choices.
25Purpose: Beta-lactam antibiotics in combination with a beta-lactamase inhibitor are the first-26 line treatment option for Haemophilus influenzae infections. However, beta-lactamase-27 independent resistance to beta-lactams is increasing. This resistance mechanism has been 28 linked to amino acid substitutions in the penicillin-binding protein 3 (PBP3), but how these 29 substitutions lead to decreased binding affinities to certain beta-lactam antimicrobials 30 remains unknown. 31
Methods:We investigated beta-lactam resistance and amino acid substitutions in PBP3 32 from fifty-three clinical isolates of H. influenzae collected in Switzerland from January to April 33 2016. Identification of key polymorphisms and classification of strains into PBP3 amino acid 34 substitution groups I, II, and M was done as previously described. Based on published PBP3 35 crystal structures, we investigated how the group-specific amino acid substitutions impact the 36 beta-lactam binding site. 37Results: We found that both group I and group II substitutions disrupt the Asn526-Arg517-38Glu324 interaction, which might affect the configuration of the beta-lactam binding site. 39Amino acid substitutions in group M strains are distant from the active site and have most 40 likely no impact on beta-lactam binding. In accordance with this observation, all group M 41 strains showed minimal inhibitory concentrations (MICs) within the susceptible range for all 42 tested antimicrobials and were not significantly different to the wild type (beta-lactamase 43 producers excluded), while group I and group II strains showed significantly higher MICs for 44 beta-lactam antimicrobials. 45Conclusion: Group M strains are phenotypically equal to the wild type, while amino acid 46 substitutions of group I and group II might affect the beta-lactam binding through a common 47 mechanism by disrupting the Asn526-Arg517-Glu324 interaction. 48 49
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.